Literature DB >> 20654625

Molecular basis for complement recognition and inhibition determined by crystallographic studies of the staphylococcal complement inhibitor (SCIN) bound to C3c and C3b.

Brandon L Garcia1, Kasra X Ramyar, Apostolia Tzekou, Daniel Ricklin, William J McWhorter, John D Lambris, Brian V Geisbrecht.   

Abstract

The human complement system plays an essential role in innate and adaptive immunity by marking and eliminating microbial intruders. Activation of complement on foreign surfaces results in proteolytic cleavage of complement component 3 (C3) into the potent opsonin C3b, which triggers a variety of immune responses and participates in a self-amplification loop mediated by a multi-protein assembly known as the C3 convertase. The human pathogen Staphylococcus aureus has evolved a sophisticated and potent complement evasion strategy, which is predicated upon an arsenal of potent inhibitory proteins. One of these, the staphylococcal complement inhibitor (SCIN), acts at the level of the C3 convertase (C3bBb) and impairs downstream complement function by trapping the convertase in a stable but inactive state. Previously, we have shown that SCIN binds C3b directly and competitively inhibits binding of human factor H and, to a lesser degree, that of factor B to C3b. Here, we report the co-crystal structures of SCIN bound to C3b and C3c at 7.5 and 3.5 A limiting resolution, respectively, and show that SCIN binds a critical functional area on C3b. Most significantly, the SCIN binding site sterically occludes the binding sites of both factor H and factor B. Our results give insight into SCIN binding to activated derivatives of C3, explain how SCIN can recognize C3b in the absence of other complement components, and provide a structural basis for the competitive C3b-binding properties of SCIN. In the future, this may suggest templates for the design of novel complement inhibitors based upon the SCIN structure. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C3 convertase; Complement; Immune evasion; Staphylococcus aureus; complement inhibitor

Mesh:

Substances:

Year:  2010        PMID: 20654625      PMCID: PMC2930029          DOI: 10.1016/j.jmb.2010.07.029

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  39 in total

Review 1.  Staphylococcal innate immune evasion.

Authors:  Suzan H M Rooijakkers; Kok P M van Kessel; Jos A G van Strijp
Journal:  Trends Microbiol       Date:  2005-10-19       Impact factor: 17.079

2.  Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases.

Authors:  Suzan H M Rooijakkers; Maartje Ruyken; Anja Roos; Mohamed R Daha; Julia S Presanis; Robert B Sim; Willem J B van Wamel; Kok P M van Kessel; Jos A G van Strijp
Journal:  Nat Immunol       Date:  2005-08-07       Impact factor: 25.606

Review 3.  The central role of the alternative complement pathway in human disease.

Authors:  Joshua M Thurman; V Michael Holers
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

Review 4.  Immune evasion by staphylococci.

Authors:  Timothy J Foster
Journal:  Nat Rev Microbiol       Date:  2005-12       Impact factor: 60.633

Review 5.  Complement evasion by human pathogens.

Authors:  John D Lambris; Daniel Ricklin; Brian V Geisbrecht
Journal:  Nat Rev Microbiol       Date:  2008-02       Impact factor: 60.633

6.  Staphylococcal complement inhibitor: structure and active sites.

Authors:  Suzan H M Rooijakkers; Fin J Milder; Bart W Bardoel; Maartje Ruyken; Jos A G van Strijp; Piet Gros
Journal:  J Immunol       Date:  2007-09-01       Impact factor: 5.422

7.  Multiple binding sites in the interaction between an extracellular fibrinogen-binding protein from Staphylococcus aureus and fibrinogen.

Authors:  M Palma; D Wade; M Flock; J I Flock
Journal:  J Biol Chem       Date:  1998-05-22       Impact factor: 5.157

8.  Structures of complement component C3 provide insights into the function and evolution of immunity.

Authors:  Bert J C Janssen; Eric G Huizinga; Hans C A Raaijmakers; Anja Roos; Mohamed R Daha; Kristina Nilsson-Ekdahl; Bo Nilsson; Piet Gros
Journal:  Nature       Date:  2005-09-22       Impact factor: 49.962

9.  A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family.

Authors:  Daniel Ricklin; Apostolia Tzekou; Brandon L Garcia; Michal Hammel; William J McWhorter; Georgia Sfyroera; You-Qiang Wu; V Michael Holers; Andrew P Herbert; Paul N Barlow; Brian V Geisbrecht; John D Lambris
Journal:  J Immunol       Date:  2009-07-22       Impact factor: 5.422

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  18 in total

1.  Crystal structure of C5b-6 suggests structural basis for priming assembly of the membrane attack complex.

Authors:  Alexander E Aleshin; Richard G DiScipio; Boguslaw Stec; Robert C Liddington
Journal:  J Biol Chem       Date:  2012-04-12       Impact factor: 5.157

2.  Inhibition of the Complement Alternative Pathway by Chemically Modified DNA Aptamers That Bind with Picomolar Affinity to Factor B.

Authors:  Xin Xu; Chi Zhang; Dalton T Denton; Daniel O'Connell; Daniel W Drolet; Brian V Geisbrecht
Journal:  J Immunol       Date:  2021-01-08       Impact factor: 5.422

Review 3.  Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins.

Authors:  Brandon L Garcia; Kasra X Ramyar; Daniel Ricklin; John D Lambris; Brian V Geisbrecht
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  A structurally dynamic N-terminal helix is a key functional determinant in staphylococcal complement inhibitor (SCIN) proteins.

Authors:  Brandon L Garcia; Brady J Summers; Kasra X Ramyar; Apostolia Tzekou; Zhuoer Lin; Daniel Ricklin; John D Lambris; John H Laity; Brian V Geisbrecht
Journal:  J Biol Chem       Date:  2012-12-11       Impact factor: 5.157

5.  The extracellular adherence protein from Staphylococcus aureus inhibits the classical and lectin pathways of complement by blocking formation of the C3 proconvertase.

Authors:  Jordan L Woehl; Daphne A C Stapels; Brandon L Garcia; Kasra X Ramyar; Andrew Keightley; Maartje Ruyken; Maria Syriga; Georgia Sfyroera; Alexander B Weber; Michal Zolkiewski; Daniel Ricklin; John D Lambris; Suzan H M Rooijakkers; Brian V Geisbrecht
Journal:  J Immunol       Date:  2014-11-07       Impact factor: 5.422

6.  Identification of C3b-Binding Small-Molecule Complement Inhibitors Using Cheminformatics.

Authors:  Brandon L Garcia; D Andrew Skaff; Arindam Chatterjee; Anders Hanning; John K Walker; Gerald J Wyckoff; Brian V Geisbrecht
Journal:  J Immunol       Date:  2017-03-15       Impact factor: 5.422

7.  Diversity in the C3b [corrected] contact residues and tertiary structures of the staphylococcal complement inhibitor (SCIN) protein family.

Authors:  Brandon L Garcia; Brady J Summers; Zhuoer Lin; Kasra X Ramyar; Daniel Ricklin; Divya V Kamath; Zheng-Qing Fu; John D Lambris; Brian V Geisbrecht
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

8.  Identification of peptidic inhibitors of the alternative complement pathway based on Staphylococcus aureus SCIN proteins.

Authors:  Brady J Summers; Brandon L Garcia; Jordan L Woehl; Kasra X Ramyar; Xiaolan Yao; Brian V Geisbrecht
Journal:  Mol Immunol       Date:  2015-06-04       Impact factor: 4.407

9.  Expression, purification, and characterization of a human complement component C3 analog that lacks the C-terminal C345c domain.

Authors:  Kasra X Ramyar; Xin Xu; Natalie M White; Andrew Keightley; Brian V Geisbrecht
Journal:  J Immunol Methods       Date:  2019-07-15       Impact factor: 2.303

Review 10.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.